SCHEMBL3030487

SCHEMBL3030487

CC(O)CNC(=O)c1cc2c(s1)CCc1ccccc1C2=C1CCN(C)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.51
CYP2C19 P33261 1/20 0.51
PRMT5 O14744 6/20 0.49
WDR77 Q9BQA1 6/20 0.49
MAPT P10636 2/20 0.48
MEN1 O00255 1/20 0.48
MAPK1 P28482 1/20 0.48
KMT2A Q03164 1/20 0.48
LMNA P02545 1/20 0.48
ADRB2 P07550 1/20 0.48
CHRM2 P08172 1/20 0.48
HTR1A P08908 1/20 0.48
ADRA2A P08913 1/20 0.48
CHRM1 P11229 1/20 0.48
DRD2 P14416 1/20 0.48
ADRA2B P18089 1/20 0.48
ADRA2C P18825 1/20 0.48
CNR1 P21554 1/20 0.48
DRD1 P21728 1/20 0.48
SLC6A2 P23975 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3046588 0.86 DRD2 (0.50) CYP2D6CYP2C19PRMT5WDR77MAPT
SCHEMBL3044383 0.86 MAPT (0.50) CYP2D6CYP2C19PRMT5WDR77MAPT
SCHEMBL3046215 0.86 SETD7 (0.57) CYP2D6CYP2C19MAPTMEN1MAPK1
SCHEMBL3030462 0.85 MAPT (0.49) CYP2D6CYP2C19PRMT5WDR77MAPT
SCHEMBL3044088 0.85 MAPT (0.49) CYP2D6CYP2C19PRMT5WDR77MAPT
SCHEMBL3037289 0.85 CYP2D6 (0.49) CYP2D6CYP2C19PRMT5WDR77MAPT
SCHEMBL3044352 0.85 MAPT (0.49) CYP2D6CYP2C19PRMT5WDR77MAPT
SCHEMBL3046581 0.85 KMT2A (0.48) CYP2D6CYP2C19PRMT5WDR77MAPT
SCHEMBL3043666 0.85 MAPK1 (0.51) CYP2D6CYP2C19PRMT5WDR77MAPT
SCHEMBL3030680 0.85 MAPT (0.48) CYP2D6CYP2C19PRMT5WDR77MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2243778-B1 PIPERIDINE DERIVATIVE NIPPON ZOKI PHARMACEUTICAL CO (JP) 2014-10-29 EP disclosed
US-8377967-B2 Piperidine derivative NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) 2013-02-19 US disclosed
US-20100331365-A1 PIPERIDINE DERIVATIVE NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) 2010-12-30 US disclosed
EP-2243778-A1 PIPERIDINE DERIVATIVE Nippon Zoki Pharmaceutical Co., Ltd. (JP) 2010-10-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331365-A1 PIPERIDINE DERIVATIVE HRH4, HRH3, HRH2 CYP2D6 729/4885CYP2C19 721/4885PRMT5 1158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.